We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .
The effects of adding torasemide to standard therapy on peak oxygen consumption, natriuretic peptides, and quality of life in patients with compensated left ventricular systolic dysfunction.
AIMS Diuretics , when used to treat congestion in patients with chronic heart failure , improve symptoms and , perhaps , prognosis but little information is available to guide their use in patients with left ventricular systolic dysfunction ( LVSD ) who are not congested . Chronic diuretic therapy causes persistent and potentially harmful neuroendocrine activation . Alternatively , in patients in whom neuroendocrine activation is blocked with angiotensin-converting enzyme (ACE)-inhibitors and beta-blockers , diuretics may be beneficial by decreasing preload and afterload and preventing congestion . We aim ed to assess the effect of the loop diuretic , torasemide on quality of life , and surrogate markers of prognosis when given to patients with LVSD who were not clinical ly congested and who were optimally treated with ACE-inhibitors ( or angiotensin receptor antagonists ) and beta-blockers . METHODS AND RESULTS Thirty patients with stable LVSD who had no clinical ly detectable fluid overload were r and omized to receive either torasemide 5 mg daily or placebo for 3 months ( Phase A ) , and after a washout phase of 2 months , cross-over was performed for 3 months ( Phase B ) . Diuretic therapy did not cause significant change in peak VO(2 ) , mean N-terminal pro-hormone brain natriuretic peptide ( NT-proBNP ) levels , or measures of quality of life compared with placebo . Diuretic therapy did however lead to significant fall in systolic and diastolic blood pressures and increase in plasma renin levels compared with placebo . CONCLUSION Diuretic therapy with torasemide is not superior to placebo in improving peak VO(2 ) or reducing NT-proBNP levels in patients with left ventricular dysfunction who are not clinical ly congested
We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .